Does tyrosine kinase inhibitor enhance the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors?
IV irinotecan given with 12 days of oral gefitinib is well tolerated in children. We observed one partial response. Gefitinib significantly enhances the bioavailability of oral irinotecan. This combination warrants further investigation, particularly with orally administered irinotecan.
Although the median constipation score was low in both groups, there was a significant association between constipation and haemorrhoids in adult patients.